Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: September 27, 2007
Last updated: October 29, 2014
Last verified: October 2014
A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is <100mg/dl for patients with high risk and <70mg/dl for patients at very high risk) are screened (office-based specialists). The doctors therapy decisions after the screening and possible reasons for these decisions will be documented. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.

Coronary Heart Disease
Carotid Stenosis
Peripheral Vascular Diseases
Diabetes Mellitus

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Non-interventional Study Investigating How Effective Secondary Prevention Patients Are Treated to Their LDL-C Targets

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Lipid profile [ Time Frame: At screening and 8-5 weeks after screening ]
  • HbA1c profile [ Time Frame: At screening and 8-5 weeks after screening ]

Enrollment: 951
Study Start Date: July 2007
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Male and female type II diabetics with: coronary disease with event: acute coronary syndrome, status post MI, PTCT, CABG, angiographically verified), or proven atherosclerotic progression (PAVK min. IIb or S.p. revascularization, stroke/TIA, carotis-plaque: asymptomatic min. 70% or S.p. revascularization)

Inclusion Criteria:

  • Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes who already receive cholesterol-lowering therapy

Exclusion Criteria:

  • Patients who do not receive cholesterol-lowering therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00536965

Research Site
Vienna, Austria
Sponsors and Collaborators
Study Chair: Josef Patsch, MD Chair of the Austrian Atheroslerosis Society
Study Chair: Bernhard Foger, MD Co-Chair of the Austrian Atheroslerosis Society
  More Information

Responsible Party: AstraZeneca Identifier: NCT00536965     History of Changes
Other Study ID Numbers: NIS-CAT-CRE-2007/1
Study First Received: September 27, 2007
Last Updated: October 29, 2014

Keywords provided by AstraZeneca:
Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes

Additional relevant MeSH terms:
Diabetes Mellitus
Heart Diseases
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Vascular Diseases
Peripheral Vascular Diseases
Peripheral Arterial Disease
Carotid Stenosis
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Lipid Metabolism Disorders
Carotid Artery Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases processed this record on May 25, 2017